Stockscreener 앱 받기
12.56
31.11%
2.98
시간 외 거래:
12.50
-0.06
-0.48%
전일 마감가:
$9.58
열려 있는:
$9.58
하루 거래량:
93,812
Relative Volume:
13.95
시가총액:
$254.03M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-24.11%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$8.08
$15.50
1주일 범위
$6.10
$16.00
52주 변동 폭
$6.10
$21.00
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
NTHI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
12.56 | 254.03M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Neonc Technologies Holdings Inc 주식(NTHI)의 최신 뉴스
Neonc Technologies appoints new accounting firm By Investing.com - Investing.com Canada
Neonc Technologies appoints new accounting firm - Investing.com India
NeOnc Technologies Partners with CBCC for Clinical Expansion - TipRanks
NeOnc Technologies receives RPDD for NEO100 - TipRanks
NeOnc Technologies Holdings: New IPO gets a Rare Pediatric Disease Designation and a 37.92% Jump in the Market - RagingBull
NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation - MarketScreener
NeOnc Falls Despite FDA Nod - Baystreet.ca
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric - GlobeNewswire
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - Yahoo Finance
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - The Manila Times
NeOnc Technologies Expands Global Clinical Trial Network - GlobeNewswire
NeOnc Technologies Holdings, Inc. Rings the Opening Bell - Nasdaq
NTHI IPO NewsBiotech NeOnc Technologies' share registration declared effective ahead of Nasdaq direct listing - renaissancecapital.com
NeOnc Technologies Holdings Announces Effectiveness of - GlobeNewswire
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market - Yahoo Finance
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors - Yahoo Finance
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors - GlobeNewswire
NeOnc Technologies Holdings, Inc. Appoints Dr. Steven L. Giannotta to Board of Directors - Nasdaq
Nasdaq’s opening bell will ring for USC research startup NeOnc - USC Today
Planet TV Studios Airing “New Frontiers” Episode on NeOnc Technologies Holdings, Inc. – Saturday, March 15, - EIN News
Expanding horizons: NeOnc Technologies’ bold vision - The Business Journals
NeOnc Technologies plans to go public through direct listing - AlphaStreet
NeOnc Technologies has another go at a Nasdaq listing - pharmaphorum
Cancer Drug Co. Revives Bid To Go Public Via Direct Listing - Law360
NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024 - GlobeNewswire
A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets - MedCity News
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate - GlobeNewswire
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors - BioSpace
NeOnc Technologies Receives FDA Approval to Expand - GlobeNewswire
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status - GlobeNewswire
NeOnc Technologies Holdings: NTHI IPO, Health CarePhase 2 biotech developing intranasal and oral therapies for brain cancer. - renaissancecapital.com
NeOnc Technologies Holdings Receives FDA Authorization to - GlobeNewswire
NeOnc Technologies Appoints Sidra Medicine CEO and Forbes - GlobeNewswire
NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’ - GlobeNewswire
Neonc Technologies Holdings Inc (NTHI) 재무 분석
Neonc Technologies Holdings Inc (NTHI)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
10.70%
자본화:
|
볼륨(24시간):